Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.
2.

Addressing Variability and Heterogeneity of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Biendarra-Tiegs SM, Secreto FJ, Nelson TJ.

Adv Exp Med Biol. 2019 Mar 10. doi: 10.1007/5584_2019_350. [Epub ahead of print]

PMID:
30850960
3.

Disease modeling studies using induced pluripotent stem cells: are we using enough controls?

Johnson AA, Andrews-Pfannkoch C, Nelson TJ, Pulido JS, Marmorstein AD.

Regen Med. 2017 Dec 15. doi: 10.2217/rme-2017-0101. [Epub ahead of print]

PMID:
29243553
4.

Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality.

Secreto FJ, Li X, Smith AJ, Bruinsma ES, Perales-Clemente E, Oommen S, Hawse G, Hrstka SCL, Arendt BK, Brandt EB, Wigle DA, Nelson TJ.

Stem Cells Transl Med. 2017 Oct;6(10):1829-1839. doi: 10.1002/sctm.17-0116. Epub 2017 Sep 19.

5.

Current Interventional and Surgical Management of Congenital Heart Disease: Specific Focus on Valvular Disease and Cardiac Arrhythmias.

Holst KA, Said SM, Nelson TJ, Cannon BC, Dearani JA.

Circ Res. 2017 Mar 17;120(6):1027-1044. doi: 10.1161/CIRCRESAHA.117.309186. Review.

PMID:
28302746
6.

NOTCH1-Dependent Nitric Oxide Signaling Deficiency in Hypoplastic Left Heart Syndrome Revealed Through Patient-Specific Phenotypes Detected in Bioengineered Cardiogenesis.

Hrstka SC, Li X, Nelson TJ; Wanek Program Genetics Pipeline Group.

Stem Cells. 2017 Apr;35(4):1106-1119. doi: 10.1002/stem.2582. Epub 2017 Mar 5.

7.

Natural underlying mtDNA heteroplasmy as a potential source of intra-person hiPSC variability.

Perales-Clemente E, Cook AN, Evans JM, Roellinger S, Secreto F, Emmanuele V, Oglesbee D, Mootha VK, Hirano M, Schon EA, Terzic A, Nelson TJ.

EMBO J. 2016 Sep 15;35(18):1979-90. doi: 10.15252/embj.201694892. Epub 2016 Jul 19.

8.

Stem Cell Therapy and Congenital Heart Disease.

Nelson TJ, Cantero Peral S.

J Cardiovasc Dev Dis. 2016 Jul 5;3(3). pii: E24. doi: 10.3390/jcdd3030024. Review.

9.

Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells.

Aho JM, Dietz AB, Radel DJ, Butler GW, Thomas M, Nelson TJ, Carlsen BT, Cassivi SD, Resch ZT, Faubion WA, Wigle DA.

Stem Cells Transl Med. 2016 Oct;5(10):1375-1379. Epub 2016 Jun 24.

10.

Mapping transcriptome profiles of in vitro iPSC-derived cardiac differentiation to in utero heart development.

Li X, Campbell KA, Biendarra SM, Terzic A, Nelson TJ.

Genom Data. 2015 Dec 30;7:129-30. doi: 10.1016/j.gdata.2015.12.022. eCollection 2016 Mar.

11.

Hypoplastic left heart syndrome: What's next?

Burkhart HM, Thompson JL, Nelson TJ.

J Thorac Cardiovasc Surg. 2016 Apr;151(4):909-10. doi: 10.1016/j.jtcvs.2015.12.032. Epub 2015 Dec 22. No abstract available.

12.

Modeling structural and functional deficiencies of RBM20 familial dilated cardiomyopathy using human induced pluripotent stem cells.

Wyles SP, Li X, Hrstka SC, Reyes S, Oommen S, Beraldi R, Edwards J, Terzic A, Olson TM, Nelson TJ.

Hum Mol Genet. 2016 Jan 15;25(2):254-65. doi: 10.1093/hmg/ddv468. Epub 2015 Nov 24.

13.

Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery.

Campbell KA, Terzic A, Nelson TJ.

Regen Med. 2015;10(6):773-83. doi: 10.2217/rme.15.41. Epub 2015 Oct 6. Review.

14.

Ebstein anomaly review: what's now, what's next?

Dearani JA, Mora BN, Nelson TJ, Haile DT, O'Leary PW.

Expert Rev Cardiovasc Ther. 2015 Oct;13(10):1101-9. doi: 10.1586/14779072.2015.1087849. Epub 2015 Sep 10. Review.

PMID:
26357983
15.

Nos3-/- iPSCs model concordant signatures of in utero cardiac pathogenesis.

Campbell KA, Li X, Biendarra SM, Terzic A, Nelson TJ.

J Mol Cell Cardiol. 2015 Oct;87:228-36. doi: 10.1016/j.yjmcc.2015.08.021. Epub 2015 Sep 4.

PMID:
26344701
16.

Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome.

Theis JL, Hrstka SC, Evans JM, O'Byrne MM, de Andrade M, O'Leary PW, Nelson TJ, Olson TM.

Hum Genet. 2015 Sep;134(9):1003-11. doi: 10.1007/s00439-015-1582-1. Epub 2015 Jul 12.

PMID:
26164125
17.

Regenerative Therapy Prevents Heart Failure Progression in Dyssynchronous Nonischemic Narrow QRS Cardiomyopathy.

Yamada S, Arrell DK, Martinez-Fernandez A, Behfar A, Kane GC, Perez-Terzic CM, Crespo-Diaz RJ, McDonald RJ, Wyles SP, Zlatkovic-Lindor J, Nelson TJ, Terzic A.

J Am Heart Assoc. 2015 May 11;4(5). pii: e001614. doi: 10.1161/JAHA.114.001614.

18.

Human umbilical cord blood-derived mononuclear cells improve murine ventricular function upon intramyocardial delivery in right ventricular chronic pressure overload.

Oommen S, Yamada S, Cantero Peral S, Campbell KA, Bruinsma ES, Terzic A, Nelson TJ.

Stem Cell Res Ther. 2015 Mar 26;6:50. doi: 10.1186/s13287-015-0044-y.

19.

Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system.

Cantero Peral S, Burkhart HM, Oommen S, Yamada S, Nyberg SL, Li X, O'Leary PW, Terzic A, Cannon BC, Nelson TJ; Wanek Program Porcine Pipeline Group.

Stem Cells Transl Med. 2015 Feb;4(2):195-206. doi: 10.5966/sctm.2014-0195. Epub 2015 Jan 5.

20.

Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells.

Burkhart HM, Qureshi MY, Peral SC, O'Leary PW, Olson TM, Cetta F, Nelson TJ; Wanek Program Clinical Pipeline Group.

J Thorac Cardiovasc Surg. 2015 Mar;149(3):e35-7. doi: 10.1016/j.jtcvs.2014.10.093. Epub 2014 Oct 24. No abstract available.

Supplemental Content

Loading ...
Support Center